TABLE 3.

Cancer therapies which influence cardiac metabolism.

Group of drugs	Molecular target	Metabolic alterations in the heart
VEGF inhibitors, e.g., Bevacizumab and tyrosine kinase inhibitors	GLUT-1 (Giordano et al., 2001), PGC-1α (Kivela et al., 2014), Akt (Kivela et al., 2014; Pandey et al., 2018)	• Arterial hypertension (Pandey et al., 2018) • Shift from FAO to glucose uptake in cardiomyocytes (Kivela et al., 2014)
Anthracyclines, e.g., doxorubicin	TopoIIβ (Zhang et al., 2012), PGC-1α (Zhang et al., 2012), IL-6 (Elsea et al., 2015)	• Increased apoptosis (Elsea et al., 2015; Willis et al., 2019) • Cachexia (Elsea et al., 2015; Willis et al., 2019) • Mitochondrial dysformation (Elsea et al., 2015)

FAO, Fatty acid oxidation; GLUT-1, Glucose transporter 1; IL, Interleukin; PGC-1α, Peroxisome proliferator-activated receptor-gamma coactivator; Akt, Protein kinase B; TopoIIβ, Topoisomerase IIβ; VEGF, Vascular endothelial growth factor.